Jake, your friend asks the right question, and the answer

New Post Public Reply Private Reply Replies (3) Message Board
MGK_2 Jake2212 #163070
612
Jake, your friend asks the right question, and the answer is yes, with a specific explanation as to why.
The choice of TAS-102 plus bevacizumab over FOLFOX as the CLOVER backbone was an informed selection of the chemotherapy agent whose specific mode of killing is most complementary to what leronlimab does upstream of the tumor cell's DNA repair machinery .

Here is what makes TAS-102 categorically different from FOLFOX at the molecular level. Trifluridine, the active cytotoxic component of TAS-102, is incorporated directly into tumor cell DNA where it gradually accumulates, and the amount of FTD incorporation in DNA and antitumor activity were positively and significantly correlated. The results suggest that TAS-102 exerts its antitumor activity predominantly due to its DNA incorporation rather than thymidylate synthase inhibition. This is not a subtle distinction. The degree of incorporation of FTD into DNA ranges from approximately 10-fold up to 700-fold greater in comparison with that of fluorodeoxyuridine, and FTD incorporation into DNA is the primary mechanism of antitumor activity with oral administration . 
https://www.prnewswire.com/news-releases/skyr...70300.html  

https://seekingalpha.com/pr/19762611-u-s-fda-...-portfolio  

FOLFOX, by contrast, works primarily through oxaliplatin-induced DNA crosslinks and fluorouracil-mediated thymidylate synthase inhibition, which blocks the synthesis of new DNA rather than directly corrupting the existing DNA strand . The repair pathway the tumor cell uses to survive FOLFOX damage is different from the repair pathway it uses to survive TAS-102-induced strand corruption.

Now here is where the CCR5 interaction becomes specifically important to the CLOVER backbone choice. FTD induces cell cycle arrest at the G2/M phase, whereas 5-FU appears to induce a G1 and S phase arrest. G2/M is the checkpoint at which the cell has already replicated its DNA and is preparing to divide. A cell arrested at G2/M with FTD incorporated into its DNA strand is a cell that has already committed its replication resources and cannot retreat. The CCR5-dependent cell cycle regulators documented in the June 2026 Frontiers in Immunology phosphoproteomics paper, CEP131, KHDRBS1, and MAPK6, are all active in the G2/M transition and mitotic entry phases. When leronlimab abolishes their phosphorylation by blocking CCR5, the tumor cell loses the signaling infrastructure that would normally allow it to navigate the G2/M checkpoint and complete division after TAS-102 has incorporated into its DNA. The tumor cell is simultaneously facing corrupted DNA and a disrupted G2/M checkpoint signaling cascade. That combination is more lethal than either insult alone. 
https://pmc.ncbi.nlm.nih.gov/articles/PMC8423937/  

FOLFOX's G1/S arrest mechanism does not engage the same G2/M checkpoint machinery that CCR5-dependent signaling governs. The synergy between leronlimab and TAS-102 at the G2/M checkpoint is specific to TAS-102's trifluridine incorporation mechanism and not equally replicated by fluoropyrimidine-based replication inhibition.

There is a second dimension to the backbone choice that the bevacizumab component addresses.
Tipiracil, the second component of TAS-102, may also have antiangiogenic effects through inhibition of thymidine phosphorylase. Bevacizumab adds VEGF-A blockade and vascular normalization to an already anti-angiogenic backbone, creating a dual anti-angiogenic effect alongside the direct DNA corruption mechanism . The FOLFOX backbone with bevacizumab, which was the basket trial regimen, provided only the bevacizumab anti-angiogenic contribution without the tipiracil component's own thymidine phosphorylase inhibition. 
https://image-ppubs.uspto.gov/dirsearch-publi...f/11584797  

Your friend's educated guess is well grounded. Dr. Lalezari and the clinical team had the basket trial data in hand when they designed CLOVER. They knew FOLFOX plus leronlimab produced a 75 percent ORR in four patients at a suboptimal dose in a heavily pretreated refractory population. The decision to replace FOLFOX with TAS-102 in a population that had already failed FOLFOX was partly a practical necessity, because CLOVER patients are fluoropyrimidine-refractory by eligibility criteria, and partly a mechanistically motivated upgrade. 

Preclinical and clinical studies demonstrate that TAS-102 is noncross-resistant with 5-fluorouracil, meaning it retains cytotoxic activity in tumors that have already developed resistance to the FOLFOX backbone. The CLOVER population is not just later in their treatment sequence than the basket trial patients. They are in a population where the fluoropyrimidine resistance mechanisms that defeated FOLFOX are specifically bypassed by TAS-102's DNA incorporation mechanism.  
https://image-ppubs.uspto.gov/dirsearch-publi...f/11584797  

The team chose TAS-102 because it kills the tumors that FOLFOX could no longer kill, it engages the G2/M checkpoint machinery that CCR5 blockade specifically impairs, and it adds a second anti-angiogenic layer through tipiracil's thymidine phosphorylase inhibition alongside bevacizumab's VEGF-A blockade. That is not a coincidence. That is an informed backbone selection by a team that understood what leronlimab was doing upstream of the tumor cell's DNA repair machinery.

Your friend's educated guess has published peer-reviewed mechanism of action support underneath it. 
Jay and his friends very likely know precisely what they chose and why.  Yes, this is what they know.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Perigon Builds Its Investment Bench for the Next Leg

Updated Category News Views 129

Perigon is rearranging the engine room before the next growth spurt gets noisy. The firm has named Christopher Broderick Director of Investments and Research, added two trading associates, and put another brick behind the broader operating structure Rafia Hasan has been assembling since taking on the chief operating officer role in August. That may sound like ordinary...

Continue Reading
Teachstone’s Bronze Award Puts Classroom Quality in Focus

Updated Category News Views 36

Small Classroom Moments Finally Get Their Due A child’s hesitant question can disappear in the noise of a busy classroom, which is precisely why Teachstone’s latest recognition deserves more than the usual polite golf clap. The Charlottesville-based Certified B Corporation received a Bronze Anthem Award for its “From Measurement to Momentum” initiative, in the...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 100

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 90

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 72

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 88

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading

Top 5 Most Recently Viewed Articles

Specialty1 Partners Drives New Growth Through Partnerships

Updated Category News Views 227

Specialty1 Partners Fuels Growth with Innovative Model Specialty1 Partners (S1P) has emerged as a leader in the specialty dental partnership sector, focusing on aiding Endodontists, Periodontists, and Oral Surgeons in elevating their practices. Their innovative joint venture model is increasingly attracting dental specialists eager to transition from associates to...

Continue Reading
Union Pacific in Talks for Major Norfolk Southern Merger

Updated Category News Views 263

Union Pacific's Ambitious Merger Talks Union Pacific Corp. (NYSE: UNP) is reportedly engaged in preliminary discussions to acquire Norfolk Southern Corp. (NYSE: NSC), marking a prospective mega-merger in the railroad industry. While details are still emerging, the implications of such a merger could significantly reshape the freight transport landscape across the United...

Continue Reading
Great Elm Capital Corp.'s Impressive Second Quarter Performance

Updated Category News Views 147

Overview of Financial Achievements Great Elm Capital Corp. (NASDAQ: GECC) has recently released its financial performance report for the second quarter, demonstrating remarkable growth and a prosperous quarter for the company. This update is essential for investors and stakeholders keen on understanding the company's current financial health and future prospects. Record...

Continue Reading
Scandinavian Tobacco Group Updates on Share Buy-back Activities

Updated Category News Views 211

Scandinavian Tobacco Group A/S launched a significant share buy-back program back in November, worth up to DKK 850 million. The move aimed at adjusting the company's capital structure and meeting obligations tied to its share-based incentive programs. This isn’t just a random act; it’s a strategic ploy in a competitive market that’s meant to bolster their stock...

Continue Reading
Breakthrough Outcomes of Telitacicept in Sjögren's Syndrome Study

Updated Category News Views 220

Exciting Developments in Telitacicept Phase III Trial Results The Phase III clinical trial results for Telitacicept are sparking significant interest, particularly within the realm of Sjögren's Syndrome. This autoimmune condition can severely affect patients' quality of life due to symptoms like dry mouth and dry eyes, among others. Recently, announcements surrounding...

Continue Reading